US lawmakers probe Chinese clinical trial sites for potential military links involving major drugmakers

A bipartisan group of U.S. lawmakers has launched a national‑security investigation into whether several large pharmaceutical companies participated in clinical trials at Chinese sites that may have supported the country's military capabilities.

The inquiry focuses on the role of these trials in advancing technologies that could be used for defense purposes, prompting lawmakers to request documents and testimony from the companies involved.

Separately, FDA scientists indicated that current evidence does not support allowing certain peptide products to be compounded by pharmacies, highlighting ongoing regulatory scrutiny of peptide manufacturing.